Nicholas Coupe, MBBS, PhD, oncologist, Oxford University Hospitals, NHS Foundation Trust, discusses the investigation of IMM60 plus pembrolizumab (Keytruda) in patients with advanced melanoma or metastatic non-small cell lung cancer (NSCLC).
2023
Dr Monga on the Investigation of PRT811 in High-Grade Glioma or Uveal Melanoma
Varun Monga, MD, clinical associate professor, Internal Medicine, Hematology, Oncology, and Blood and Marrow Transplantation, University of Iowa, discusses the investigation of the protein arginine methyltransferase 5 (PRMT5) brain-penetrant inhibitor PRT811 in patients with recurrent high-grade glioma or uveal melanoma.
Researchers uncover potential biomarkers of positive response to immunotherapy
Scientists at the UCLA Jonsson Comprehensive Cancer Center have identified potential new biomarkers that could indicate how someone diagnosed with metastatic melanoma will respond to immunotherapy treatment.
Anti–LAG-3/PD-1 Combination Under Investigation as Adjuvant Therapy in High-Risk Melanoma
The combination of fianlimab and cemiplimab-rwlc (Libtayo) represents a wave of novel anti–LAG-3/PD-1 treatments being explored in patients with melanoma at high risk for relapse, according to the rationale and design of an ongoing phase 3 trial (NCT05608291) that were presented at the 2023 ASCO Annual Meeting.